BD Neopak™ prefilled syringes

NegotiableUpdate on 05/06

Model

Nature of the Manufacturer: Producers

Product Category

Place of Origin

Online Consult

Overview

BD Neopak Pre filled syringe, this is a new pre filled platform launched by BD (Bidi Medical), called Hypak Upgraded version of the biopharmaceutical series, focusing on the safety, compatibility, and rapid market launch of biologics (especially chronic disease biologics injected subcutaneously). Standard capacities: 1mL, 2.25mL; There is also Neopak XtraFlow Series expansion, $r $n needle specifications: 27G – 29G, can choose conventional wall/thin wall/special thin wall, cut edge/small round edge flange, compatible with different automatic injection pens

Product Details

BD Neopak ™ prefilled syringes

Item Number	capacity	Needle specifications	Flange design	Needle wall/coating	remark
47592710	1mL	29G， 1	Circular small flange	thin-walled	Standard version, SCF sterile can be directly filled
47601210	2.25mL	27G， 1	Circular flange	thin-walled	XSi coating, suitable for silicon sensitive drugs
47592810	1mL	27G， 1	Circular small flange	thin-walled	Standard version, suitable for low viscosity drugs
47593010	1mL	26G， 1	Circular small flange	thin-walled	Standard version, meeting general injection needs
47601310	2.25mL	29G， 1	Circular flange	thin-walled	XSi coating, suitable for highly sensitive biologics
47601410	2.25mL	30G， 1	Circular flange	thin-walled	XSi coating, suitable for low-dose precision injectionshoot

1、 Core positioning and applicable scenarios

core positioning：BD Neopak ™ Pre filled syringes,Pre filled glass drug packaging materials for biopharmaceuticals, balancing drug compatibility, injection performance, and production efficiency, suitable for both clinical and home administration scenarios, supporting automatic injector integration, and assisting in the rapid market launch and commercial production of biopharmaceuticals
Target formulationMonoclonal antibodies, GLP-1 hypoglycemic drugs, anti-inflammatory drugs, cardiovascular drugs, rare disease treatment drugs, etcHigh value biologicsEspecially suitable forHigh viscosity (≤ 100cP)andSilicon sensitive typemedicine
Application scenarios: Clinical research, commercial production, self injection of patients at home (such as long-term treatment of diabetes and autoimmune diseases)

2、 Key technologies and specification parameters

1. Core Technology Highlights

technology	value
XSi Cross linked Silicon Coating	Stabilize the silicon layer structure, reduce sub visible particles (about 50% less than traditional coatings), lower the risk of silicon migration, and improve the compatibility of silicon sensitive drugs
Low/ultra-low tungsten glass	Standard low tungsten+optional ultra-low tungsten configuration, reducing tungsten leaching and lowering drug oxidation and immunogenicity risks
DuraShield glass reinforcement	Enhance glass strength, reduce breakage rate, fully indexed production process eliminates glass to glass contact, and reduces appearance defects by 80%
XtraFlow ™ Injection system	8mm short needle+thin-walled needle tube, reducing injection force by 30% -50% (≤ 20N), improving patient compliance
Optimize adhesive curing	Reduce leachables, lower the risk of drug container interactions, and ensure the activity of biopharmaceuticals

2. Basic specifications

capacity: 1mL, 2.25mL (suitable for mainstream biopharmaceutical dosage requirements)
needle26G-30G, 8mm standard length, thin-walled design reduces injection resistance
flangeCircular small flange/circular flange (compatible with automatic injectors and manual operation)
Dead volume≤ 5 μ L (reduces drug residue and minimizes filling waste)
Aseptic stateSCF is sterile and can be directly filled, shortening the drug production process

3、 Core advantages and value proposition

Drug compatibilityFrom glass material to coating process optimization, reducing the risk of leaching and particles, we have supported the approval of 24+biopharmaceutical indications worldwide (including Crohn's disease, atopic dermatitis, etc.)
Injection performanceLow friction push rod+short thin-walled needle combination significantly reduces injection force, improves patient comfort, and reduces home injection anxiety
Production efficiency improvementFull index production process+low appearance defect rate+ready to use sterile design, reducing scrap rate, shortening market cycle, and reducing total cost of ownership by 15% -20%
Flexible integration capabilityCompatible with mainstream automatic injectors (such as Ypsomed YpsoMate) ®）， Support the development of drug device combinations and provide customized components such as needle sockets and protective caps
Compliance AssuranceCompliant with international standards such as ISO 11040 and USP<1664>, with registration qualifications for pharmaceutical packaging materials in multiple countries worldwide, to assist in cross-border applications

4、 Supply Chain and Market Performance

production capacity layoutGlobal multi base production, with added production capacity in the United States by 2026, reaching hundreds of millions of units annually to ensure supply stability
Customer approvalWidely adopted by excellent biopharmaceutical companies and CDMOs worldwide, it has become a leading choice for pre filled packaging of biopharmaceuticalstop choice
Sustainable developmentOptimize material usage, reduce carbon emissions in the production process, in line with the trend of green production in the pharmaceutical industry